DEF 14A: Caribou Biosciences Sets Date for 2024 Annual Stockholders Meeting

Caribou Biosciences will hold its 2024 annual meeting of stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• Caribou Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on June 13, 2024, at 7:30 a.m. pacific daylight time, in a virtual meeting format.
• The meeting will address the election of Rachel Haurwitz, Ph.D., Dara Richardson-Heron, M.D., and Natalie Sacks, M.D., as Class III Directors, each to serve until the 2027 annual meeting.
• Stockholders will also vote to ratify the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote at the meeting was April 15, 2024.
• The Notice of Internet Availability of Proxy Materials was first mailed to stockholders on or about April 25, 2024.
• As of the record date, 90,317,771 shares of common stock were issued and outstanding, each entitled to one vote.
• The Board recommends voting FOR the election of the director nominees and FOR the ratification of Deloitte & Touche LLP.
• The company's Board is divided into three classes, with directors serving three-year terms.
• The company is an emerging growth company and a smaller reporting company, which allows for scaled disclosure regarding executive compensation.
• The company's Code of Business Conduct, Scientific and Data Integrity, and Ethics applies to all employees, consultants, contractors, and directors.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the details of the upcoming annual meeting and related corporate governance matters. The sentiment is neutral to slightly positive due to the routine nature of the events and the absence of any significant negative disclosures.

Positives

• The Board is recommending well-qualified candidates for election as Class III directors.
• The Audit Committee is recommending a well-regarded firm, Deloitte & Touche LLP, as the independent registered public accounting firm.
• The company has a Code of Business Conduct, Scientific and Data Integrity, and Ethics in place.
• The company has a policy prohibiting hedging and pledging of company securities by insiders.

Negatives

• Syed Rizvi, M.D., former chief medical officer, left the company on December 31, 2023.

Risks

• The document mentions potential risks related to cyber security and data privacy, which are overseen by the audit committee.
• The document mentions that in the unlikely event that, for any reason, we are not able to convene the 2024 Annual Meeting, or if, after being convened, the meeting is interrupted and cannot be continued, including due to loss of internet connectivity or communications capabilities, power failure, or other technical difficulties, the meeting will be adjourned.

Future Outlook

The company intends to use the proceeds from the Pfizer Investment solely in connection with the development program for its allogeneic anti-BCMA CAR-T cell therapy known as CB-011 that is being evaluated in its ongoing CaMMouflage phase 1 clinical trial and/or any other single-targeted anti-BCMA CAR-T cell therapy using an anti-BCMA single-chain variable fragment owned or controlled by the company, for 36 months beginning on June 29, 2023.

Management Comments

• Thank you for your continued support of Caribou Biosciences, Inc.
• We look forward to seeing you virtually at the 2024 Annual Meeting.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, election of directors, and ratification of independent auditors. The Pfizer investment and collaboration agreement highlights the ongoing interest in the BCMA-targeted CAR-T cell therapy space, which is a competitive area within the biotechnology industry.

Comparison to Industry Standards

• The director compensation structure, including cash fees and equity grants, is generally in line with industry standards for similarly sized biotechnology companies.
• The company's executive compensation arrangements, including base salaries, bonus targets, and equity awards, are typical for companies in the biotechnology sector.
• The indemnification agreements with directors and officers are standard practice to attract and retain qualified individuals.
• The company's related party transaction policy is consistent with regulatory requirements and best practices for corporate governance.

Related Party Transactions

• On June 29, 2023, Caribou Biosciences entered into a Securities Purchase Agreement with Pfizer Inc., issuing 4,690,431 shares of common stock at $5.33 per share, for $25.0 million.
• The proceeds from the Pfizer Investment are to be used solely in connection with the development program for its allogeneic anti-BCMA CAR-T cell therapy known as CB-011.
• Caribou Biosciences and Pfizer also entered into an Information Rights Agreement, granting Pfizer a right of first negotiation (ROFN) and the right to designate one representative to serve on the company's Scientific Advisory Board (SAB).
• Caribou Biosciences and Pfizer also entered into a Voting Agreement, pursuant to which, for a period of 12 months, Pfizer agreed to cause our voting securities that Pfizer beneficially owns (within the meaning of Rules 13d-3 or 13d-5 under the Exchange Act) in excess of 4.99% of our then issued and outstanding voting securities to be voted (i) with respect to any matter directly relating to remuneration of directors, directors insurance, or indemnification or release from liability of directors, in a manner proportionally consistent with the votes properly cast for and against by holders of voting securities not beneficially owned by Pfizer, and (ii) with respect to any other matter in which Pfizer has the right to vote such voting securities, in accordance with the recommendation of our board of directors or any applicable committee thereof.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, influencing the company's direction.
• Employees are indirectly affected by the election of directors and the ratification of the accounting firm.
• The Pfizer investment and collaboration could impact the company's ability to develop and commercialize its BCMA-targeted CAR-T cell therapy, potentially benefiting patients.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the 2024 Annual Meeting of Stockholders on June 13, 2024.
• The company will continue to develop its allogeneic anti-BCMA CAR-T cell therapy program (CB-011) with the proceeds from the Pfizer investment.

Key Dates

Keywords

annual meeting, proxy statement, directors, Deloitte & Touche LLP, stockholders, corporate governance, Caribou Biosciences